内分泌学家对1型糖尿病成年人中的糖化血红蛋白标的接受性和实施
Sanchit Kaushal1, Patience Fakembe1, Ilana J Halperin2
1Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Ontario, Canada.
Canadian journal of diabetes
|January 17, 2025
概括
内分泌学家支持1型糖尿病患者的糖化血红蛋白 (A1C) 目标为7.0%,但发现很难实现. 他们承认患者的心理健康和技术使用等因素会影响目标设定.
科学领域:
- 内分泌学 在内分泌学.
- 糖尿病管理 糖尿病管理
- 临床实践 临床实践
背景情况:
- 在1型糖尿病中,糖化血红蛋白 (A1C) 的目标达到率较低.
- 评估内分泌学家对A1C目标的看法对于改善患者结果至关重要.
研究的目的:
- 评估内分泌学家对1型糖尿病护理中A1C目标≤7.0%的可接受性和实施情况.
- 探索影响个性化A1C目标设置的因素.
主要方法:
- 在线调查问卷分发给安大略省309名成年内分泌科医生.
- 使用"可接受性理论框架"评估可接受性.
- 研究了患者实现的感知,目标设定实践和影响因素.
主要成果:
- 有148名内分泌学家 (48%) 参与了调查.
- 对于A1C ≤7.0%目标的重要性 (87%) 和正确性 (75%) 的高度同意.
- 过高估计患者的成就;认识到目标的潜在不真实性,困难和患者的痛苦.
结论:
- 内分泌学家支持A1C≤7.0%的目标,但对可行性存在担忧.
- 患者的心理社会因素和技术使用 (CGM,AID) 是个性化目标的关键.
- 需要进一步研究目标差异如何影响医生与患者的讨论.
相关概念视频
Diabetes Mellitus: Overview and Type I Subtype
2.4K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.4K
Diabetes Mellitus: Type 2 and Gestational
2.2K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.2K
Diabetes: Symptoms, Diagnosis, and Complications
500
For most patients, experiencing several weeks of polyuria, polydipsia, fatigue, and significant weight loss may indicate the presence of diabetes. Furthermore, adults displaying the phenotypic appearance of type 2 diabetes (particularly those who are obese and not initially insulin-requiring), may have islet cell autoantibodies, suggesting autoimmune-mediated β cell destruction and a diagnosis of latent autoimmune diabetes of adults (LADA). The categorization of glucose homeostasis is...
500
Diabetes: Management and Pharmacotherapy
233
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
233
Insulin: Dosing Regimen and Adverse Effects
141
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
141
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165


